Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin plus pioglitazone in liposarcoma after stable disease on trabectedin
2020-005626-29Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin and pioglitazone in Liposarcoma, Myxoid/round cell liposarcoma (MRCLS) and dedifferentiated liposarcoma (DDL), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Objective response. Started Jun 2021; status: completed.
02
Drugs
trabectedinpioglitazone
03
Conditions
LiposarcomaMyxoid/round cell liposarcoma (MRCLS)dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on 2020-005626-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005626-29.